Sipai Health Technology Co. Ltd. (0314) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Sipai Health Technology Co. Ltd. HK$0.51, price HK$1.52, upside -66.3%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sipai Health Technology Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
45‑month range HK$1.18 – HK$42.10 · fair‑value band HK$0.5000 – HK$0.5100 · the HK$1.52 price screens above the HK$0.5100 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Sipai Health Technology Co. in your weekly email
Every Wednesday you see whether Sipai Health Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People's Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business.
Show more
Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People's Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business. The Specialty Pharmacy Business segment provides specialty pharmacies and value-added professional pharmacist services; focuses on innovative medicines for the treatment of oncology; pharmaceutical supply chain network for health insurance services; and other critical illnesses. The Physician Research Assistance Business segment offers pharmaceutical companies and other clinical trial institutions site management organization services, including site feasibility, site initiation, patient recruitment, patient management, data entry and document management, on-site drug management and bio-sample management, site closure, and others; and services for image management in clinical trials. The Health Insurance Services Business segment provides insurance brokerage services to insurance companies; and health management services to insurance carriers and enterprise clients. The company was founded in 2014 and is headquartered in Putuo, the People's Republic of China.
Stock analysis
Sipai Health Technology Co. Ltd. (0314) currently trades at HK$1.52, while our model-based Fair Value estimate is HK$0.5100, 66.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of HK$1.01 per share, and 0 of the 6 models we run sit above the HK$1.52 price.
Bear case: the Multiples group reads lowest at HK$0.4900, and 6 of the 6 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$0.5000 (bear) to HK$0.5100 (bull), the price of HK$1.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Sipai Health Technology Co. Ltd. reported revenue of 2.0B CNY in FY2025 versus 3.5B CNY in FY2021, a compound −12.7%/yr. Reported net income was −121M CNY in FY2025.
Key figures
Market cap HK$912M (≈ $116M) · P/S ratio 0.47 · EPS (TTM) HK$−0.1200 · Net margin −6.0% · Return on equity −12.1% · Return on assets (EBIT) −15.2% · Operating margin −3.8% · Revenue (TTM) 2.1B CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at −66%, 0314 screens richer than that median.
Fair Value models
Bear HK$0.5000Fair Value HK$0.5100Bull HK$0.5100
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−55.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.7%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.1% (2020) → −5.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Sipai Health Technology Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 78 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside−66.3% · Bottom 25%
Profitability
Return on assets−3.7% · Bottom 25%
Net margin (TTM)−6.0% · Bottom 25%
Operating margin (TTM)−3.8% · Bottom 25%
Growth and dividend
Revenue growth−61.5% · Bottom 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/B0.12× · Cheapest 25%
P/S (TTM)0.06× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 39
FUTURE (revenue growth)0· sector 12
PAST (return on equity)0· sector 27
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 58
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sipai Health Technology Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/0314
Frequently asked questions
Is Sipai Health Technology Co. Ltd. (0314) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$0.5100 versus a price of HK$1.52, about −66% upside (overvalued).
What is the fair value of 0314?
Our model-based fair value for Sipai Health Technology Co. Ltd. is HK$0.5100 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$1.52.
What is the quality score of 0314?
Sipai Health Technology Co. Ltd. has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sipai Health Technology Co. Ltd. (0314)?
Our model-based price target is the fair value of HK$0.5100 (as of Sep 27, 2026) from 6 valuation models. Cautious scenario HK$0.5000, optimistic scenario HK$0.5100. It is a calculation from audited fundamentals, not an analyst target.
What is the Sipai Health Technology Co. Ltd. stock forecast for 2026?
Our models put fair value at HK$0.5100, about −66% upside versus a price of HK$1.52 (overvalued). Cautious scenario HK$0.5000, optimistic scenario HK$0.5100. The calculation is refreshed regularly with new filings.
What is the revenue of Sipai Health Technology Co. Ltd. (0314)?
Sipai Health Technology Co. Ltd. reported trailing-twelve-month revenue of about 2.1B CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Sipai Health Technology Co. Ltd. (0314)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sipai Health Technology Co. Ltd. it is HK$0.5100 per share (as of Sep 27, 2026), against a price of HK$1.52. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Sipai Health Technology Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 0314 trades above its calculated fair value: price HK$1.52, fair value HK$0.5100, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0314?
No. The price is what the market pays today (HK$1.52); the fair value is what the company's own numbers justify (HK$0.5100). For Sipai Health Technology Co. Ltd. the two are HK$1.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sipai Health Technology Co. Ltd. worth?
The market values Sipai Health Technology Co. Ltd. at about HK$912M (market capitalisation, as of Sep 27, 2026). Per share that is HK$1.52; our models calculate a fair value of HK$0.5100 per share.
What do the bullish and bearish scenarios say about 0314?
Our models span a range for Sipai Health Technology Co. Ltd.: cautious scenario HK$0.5000, base HK$0.5100, optimistic HK$0.5100 per share (as of Sep 27, 2026, price HK$1.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sipai Health Technology Co. Ltd. (0314)?
Balance-sheet figures for Sipai Health Technology Co. Ltd. (as of Sep 27, 2026): return on equity −12.1%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 0314 from its 52-week high?
Sipai Health Technology Co. Ltd. trades at HK$1.52, about 54% below its 52-week high of HK$3.30 and 28% above the low of HK$1.18 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.5100 is for.
Which stocks are comparable to Sipai Health Technology Co. Ltd.?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sipai Health Technology Co. Ltd. stock attractive at the current price?
The data as of Sep 27, 2026: price HK$1.52, calculated fair value HK$0.5100 (−66%), Quality Score 54/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0314 calculated?
We run Sipai Health Technology Co. Ltd. through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.5100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Sipai Health Technology Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sipai Health Technology Co. Ltd. (0314)?
The closing price on Sep 30, 2026 was HK$1.52. Our model-based fair value is HK$0.5100, about −66% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sipai Health Technology Co. Ltd. right now?
The price sits above even our optimistic bull case (HK$0.5100). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (HK$0.5000 to HK$0.5100), unusually little disagreement for a valuation.
Key figures of Sipai Health Technology Co. Ltd.
How large is the market capitalisation of Sipai Health Technology Co. Ltd. (0314)?
The market capitalisation of Sipai Health Technology Co. Ltd. is HK$912M (≈ $116M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sipai Health Technology Co. Ltd. (0314)?
The price-to-sales ratio of Sipai Health Technology Co. Ltd. is 0.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sipai Health Technology Co. Ltd. (0314)?
Earnings per share at Sipai Health Technology Co. Ltd. are HK$−0.1200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sipai Health Technology Co. Ltd. (0314)?
The net margin of Sipai Health Technology Co. Ltd. is −6.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sipai Health Technology Co. Ltd. (0314)?
The return on equity (ROE) of Sipai Health Technology Co. Ltd. is −12.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sipai Health Technology Co. Ltd. (0314)?
On an EBIT basis the return on assets of Sipai Health Technology Co. Ltd. is −15.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sipai Health Technology Co. Ltd. (0314)?
The operating margin of Sipai Health Technology Co. Ltd. is −3.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sipai Health Technology Co. Ltd. (0314)?
Revenue at Sipai Health Technology Co. Ltd. is growing −61.5% versus a year earlier (3y avg −21.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sipai Health Technology Co. Ltd. (0314) generate?
The free cash flow of Sipai Health Technology Co. Ltd. is 127K CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sipai Health Technology Co. Ltd. (0314) hold?
Sipai Health Technology Co. Ltd. holds more cash than debt, 284M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sipai Health Technology Co. Ltd. in the live analysis
One click puts Sipai Health Technology Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
